Bayer’s eliapixant hits the right notes in PAGANINI cough studyBayer has released the data in its phase 2b trial of eliapixant in refractory chronic cough, as it Share XBayer’s eliapixant hits the right notes in PAGANINI cough studyhttps://pharmaphorum.com/news/bayers-eliapixant-hits-the-right-notes-in-paganini-cough-study/
Chasing Merck & Co, Bayer builds case for cough drug eliapixantBayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase Share XChasing Merck & Co, Bayer builds case for cough drug eliapixanthttps://pharmaphorum.com/news/chasing-merck-bayer-builds-case-for-cough-drug-eliapixant/
Merck’s chronic cough drug gefapixant clears phase 3 testMerck & Co/MSD’s experimental drug gefapixant has improved the frequency of coughing in a pair of phase 3 Share XMerck’s chronic cough drug gefapixant clears phase 3 testhttps://pharmaphorum.com/news/mercks-chronic-cough-drug-gefapixant-clears-phase-3-test/
